Ramesh C. Nayak, Ph.D.
Scientific Advisor
rnayak@ntiplaw.com

Practice Focus and Experience
As a Scientific Advisor for Nguyen & Tarbet, Ramesh provides in depth scientific analysis and consultation on matters relating to biotechnology, pharmaceutics and diagnostics. Ramesh has extensive industry experience in these technology areas and has provided scientific consultations for major institutions and start-up companies, including Genzyme, Massachusetts Institute of Technology, Angio-Oncology Sciences, Inc., and Multiple Sclerosis Diagnostics (MSDx), LLC.

Prior to working in the industry sector, Ramesh held several distinguished academic posts, including an Assistant Professorship at Harvard University and Tufts University.

With over two decades of research experience Ramesh has developed expertise in Biochemistry, Cell Biology and Immunology applied to medical problems such as Muscular Dystrophy and Muscle development, Autoimmune diseases such as Type 1 Diabetes, Systemic Lupus Erythematosus, Autoimmune hemolytic anemia and Multiple Sclerosis, Metabolic diseases such as Type 2 Diabetes and Vascular diseases such as the complications of Diabetes Mellitus.

Representative Matters
Ramesh’s scientific background and intellectual property work includes subject matter such as:

• biotechnology
• diagnostics
• biomarker development
• biochemistry and cellular biology
• immunology
• vascular biology
• neurobiology
• diabetes and its complications
• autoimmune diseases

Postdoctoral Training

Research Fellowships:

•

1984 - 1987

Research Fellow, Section on Immunology and Immunogenetics, Elliott P. Joslin Research Laboratory, Joslin Diabetes Center, Boston, Massachusetts

•

1984 - 1988

Research Fellow in Medicine, Harvard Medical School, Boston, Massachusetts

Academic Appointments

• Instructor in Medicine, Harvard Medical School, Boston, Massachusetts
• Assistant Professor of Medicine, Harvard Medical School, Boston, Massachusetts
• Assistant Professor of Ophthalmology, Tufts University School of Medicine, Boston, MA
• Research Assistant Professor of Physiology, Tufts University School of Medicine, Boston, MA
• Assistant Professor of Pediatrics, Tufts University School of Medicine, Boston, MA
• Research Associate Professor, Dept. of Ophthalmology, University of Arizona College of Medicine, Tucson, AZ
• Visiting Professor of Diabetology, Dept of medicine, University of Lund, Lund, Sweden

Education

• Institute of Neurology, London University, UK (Ph.D., Biochemistry, 1984)
• Plymouth University, UK (B.S., Cell Biology and Cellular Toxicology,1978)

Selected Publications

Cooke A, Hutchings P, Nayak RC. Specific and non specific suppressor cell activity in NZB mice. Immunology 1980; 40:335 342.

Morrow WJW, Nayak RC, Cooke A, Roitt IM. Apparent failure of thymic epithelium transplants to alter the course of autoimmune disease in NZB/W mice. Thymus 1982; 4:315 322.

Nayak RC. Characterization of the cell surface during human skeletal muscle differentiation. Ph.D. Thesis, 1984, University of London.

Nayak RC, Omar MAK, Rabizadeh A, Srikanta S, Eisenbarth GS. "Cytoplasmic" islet cell antibodies: Evidence that the target antigen is a sialoglycoconjugate. Diabetes 1985; 34:617 619.

Rabinowe SL, Nayak RC, Krisch K, George KL, Eisenbarth GS. Aging in man: Linear increase of a novel T cell subset defined by antiganglioside monoclonal antibody 3G5. J Exp Med 1987; 165: 1436 1441.

Colman PG, Nayak RC, Campbell IL, Eisenbarth GS. Binding of "cytoplasmic" islet cell antibodies is blocked by human pancreatic glycolipid extracts. Diabetes 1988; 37:645 652.

Nayak RC, Berman AB, George KL, Eisenbarth GS, King GL. A monoclonal antibody (3G5) defined ganglioside antigen is expressed on the cell surface on microvascular pericytes. J Exp Med 1988; 167:1003 1015.

Nayak RC, Attawia M, Cahill CJ, King GL, Ohashi H. Expression of a monoclonal antibody (3G5) defined ganglioside antigen in the renal cortex; Kidney
International 1992, 41:1638-1645.

Schuster CB, Lin A, Nayak RC, Herman IM. βCAP73: A novel β-actin specific binding protein. Cell Motility and the Cytoskeleton, 1996; 35:175-187.

Nayak RC, Herman IM. Measurement of glucose consumption by cells growing in hollow fiber cartridge bio-reactors: Use of a blood glucose self-monitoring device.
J Immunol Methods 1997; 205:109-114.

Attawia MA, Nayak RC. Circulating anti-pericyte autoantibodies in diabetic retinopathy. Retina 1999; 19: 390-400.

Cahill CJ, Nayak RC. Immunoelectron microscopic detection of tissue ganglioside antigens. J. Imm. Meth. 2000; 238: 45-53.

Helmbold P, Wohlrab J, Marsch WC and Nayak RC. Human dermal pericytes express 3G5 ganglioside: a new approach for microvessel histology. J. Cutaneous Pathol. 2001; 24: 206-210.

Nayak, R.C., Agardh, C.D., Kwok, M.G.K., Stjernquist H, Farthing-Nayak, P. and Agardh, E. Circulating Anti-Pericyte Autoantibodies are Present in Type-2 Diabetic Patients and are Associated with Non-Proliferative Retinopathy. Diabetologia. 2003; 46: 511-513.

Stramer B , Kwok MGK, Farthing-Nayak P, Fini ME, Nayak RC. Monoclonal Antibody (3G5) Defined Ganglioside: Cell Surface Marker of Corneal Keratocytes, Invest. Ophthal. Vis. Sci. 2004; 45: 807-812.

Nayak, R.C., Agardh, C.D., Kwok, M.G.K., Farthing-Nayak, P., Lynch, K.and Agardh, E. Albuminuria and Hypertension are Independently Associated with Circulating Anti-Pericyte Autoantibodies in Type 2 Diabetic Patients. Metabolism: Clinical and Experimental. 2005; 54: 188-193.

P. Helmbold, C. Lautenschlager, W. Ch. Marsch and R.C. Nayak. Pericyte involvement in microvascular ageing: identification of two phases of microvascular ageing in the human dermis. J. Invest. Derm., 2006; 126: 1419-21.

R.C. Nayak, K. Lynch, C. Gustavsson, M.G.K. Kwok, P.J. Farthing-Nayak, C-D. Agardh and E. Agardh. Circulating Anti-Pericyte Autoantibodies: A Unique Modifier of Risk of Progression of Diabetic Retinopathy in Type 2 Diabetic Patients with High Haemoglobin A1c Levels. Retina 2007; 27: 211-215